1-4 of 4
Gert-Jan Timmers
Close
Sort by
Journal Articles

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Febe Smits, Kaz Groen, Mark-David Levin, Claudia Stege, Roel JW Van Kampen, Ellen Van Der Spek, Yavuz M Bilgin, Noortje Thielen, Inger S. Nijhof, Inge Ludwig, Esther G.M. De Waal, Yorick Sandberg, Alain Kentos, Gert Jan Timmers, Josien C Regelink, Matthijs Westerman, Koen de Heer, Marie Christiane Vekemans, Nazik Durdu-Rayman, Nicole de Graauw, Maarten R. Seefat, Niels WCJ van de Donk, Paula F Ypma, Kazem Nasserinejad, Sonja Zweegman
Journal: Blood
Blood (2023) 142 (Supplement 1): 342.
https://doi.org/10.1182/blood-2023-180006
Published: 2023
Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. Van Kampen, Maria B.L. Leijs, Noortje Thielen, Matthijs Westerman, Ka Lung Wu, Inge Ludwig, Djamila Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Pieter Sonneveld, Maarten R. Seefat, Fransien Croon-de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. De Waal, Maaike Sohne, Paula F Ypma, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 80.
https://doi.org/10.1182/blood-2021-152112
Published: 2021
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, Ellen van der Spek, MD PhD, Roel J.W. Van Kampen, MD PhD, Maaike Sohne, MD, Noortje Thielen, MD PhD, Yavuz Bilgin, MD PhD, Esther G.M. De Waal, MD, Inge Ludwig, MD MSc, Maria B.L. Leijs, MD, Alain Kentos, MD, Gert Jan Timmers, MD PhD, Koen de Heer, MD, Matthijs Westerman, MD, Marie Christiane Vekemans, Nazik Durdu-Rayman, MD, Nicole C.H.P. van der Burg-de Graauw, MD, Niels W. C. J. Van De Donk, MD PhD, Pieter Sonneveld, Saskia K. Klein, MD PhD, Mark-David Levin, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 695.
https://doi.org/10.1182/blood-2019-121694
Published: 2019
Journal Articles

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Michel Van Gelder, PhD, MD, Wendim Ghidey, Martine ED Chamuleau, MD, Jan Cornelissen, MD, PhD, Eefke J Petersen, MD PhD, Simon M. G. J. Daenen, Pierre Zachee, MD, PhD, Mels Hoogendoorn, MD, PhD, Aart Beker, MD, Gert Jan Timmers, MD, PhD, Arnon P. Kater, MD PhD, Marinus H.J. Van Oers, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2883.
https://doi.org/10.1182/blood.V122.21.2883.2883
Published: 2013